Stem cell‐based cell therapy in neurological diseases: A review
Identifieur interne : 000729 ( Istex/Checkpoint ); précédent : 000728; suivant : 000730Stem cell‐based cell therapy in neurological diseases: A review
Auteurs : Seung U. Kim [Canada, Corée du Sud] ; Jean De Vellis [États-Unis]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2009-08-01.
English descriptors
- KwdEn :
Abstract
Human neurological disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), stroke, and spinal cord injury are caused by a loss of neurons and glial cells in the brain or spinal cord. Cell replacement therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases. However, the paucity of suitable cell types for cell replacement therapy in patients suffering from neurological disorders has hampered the development of this promising therapeutic approach. In recent years, neurons and glial cells have successfully been generated from stem cells such as embryonic stem cells, mesenchymal stem cells, and neural stem cells, and extensive efforts by investigators to develop stem cell‐based brain transplantation therapies have been carried out. We review here notable experimental and preclinical studies previously published involving stem cell‐based cell and gene therapies for Parkinson's disease, Huntington's disease, ALS, Alzheimer's disease, MS, stroke, spinal cord injury, brain tumor, and lysosomal storage diseases and discuss the future prospects for stem cell therapy of neurological disorders in the clinical setting. There are still many obstacles to be overcome before clinical application of cell therapy in neurological disease patients is adopted: 1) it is still uncertain what kind of stem cells would be an ideal source for cellular grafts, and 2) the mechanism by which transplantation of stem cells leads to an enhanced functional recovery and structural reorganization must to be better understood. Steady and solid progress in stem cell research in both basic and preclinical settings should support the hope for development of stem cell‐based cell therapies for neurological diseases. © 2009 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.22054
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:F588ED1FF799B4EAAFBE4AB8F6D25F4310AAA1B8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stem cell‐based cell therapy in neurological diseases: A review</title><author><name sortKey="Kim, Seung U" sort="Kim, Seung U" uniqKey="Kim S" first="Seung U." last="Kim">Seung U. Kim</name></author><author><name sortKey="De Vellis, Jean" sort="De Vellis, Jean" uniqKey="De Vellis J" first="Jean" last="De Vellis">Jean De Vellis</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F588ED1FF799B4EAAFBE4AB8F6D25F4310AAA1B8</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/jnr.22054</idno><idno type="url">https://api-v5.istex.fr/document/F588ED1FF799B4EAAFBE4AB8F6D25F4310AAA1B8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001243</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001243</idno><idno type="wicri:Area/Istex/Curation">001243</idno><idno type="wicri:Area/Istex/Checkpoint">000729</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000729</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stem cell‐based cell therapy in neurological diseases: A review</title><author><name sortKey="Kim, Seung U" sort="Kim, Seung U" uniqKey="Kim S" first="Seung U." last="Kim">Seung U. Kim</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Medical Research Institute, Chungang University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, British Columbia V6T2B5</wicri:regionArea><wicri:noRegion>British Columbia V6T2B5</wicri:noRegion></affiliation></author><author><name sortKey="De Vellis, Jean" sort="De Vellis, Jean" uniqKey="De Vellis J" first="Jean" last="De Vellis">Jean De Vellis</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Mental Retardation Research Center, University of California Los Angeles School of Medicine, Los Angeles</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-08-01">2009-08-01</date><biblScope unit="volume">87</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="2183">2183</biblScope><biblScope unit="page" to="2200">2200</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">F588ED1FF799B4EAAFBE4AB8F6D25F4310AAA1B8</idno><idno type="DOI">10.1002/jnr.22054</idno><idno type="ArticleID">JNR22054</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>cell therapy</term><term>embryonic stem cell</term><term>gene transfer</term><term>mesenchymal stem cell</term><term>neural stem cell</term><term>neurological diseases</term><term>stem cell</term><term>transplantation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human neurological disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), stroke, and spinal cord injury are caused by a loss of neurons and glial cells in the brain or spinal cord. Cell replacement therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases. However, the paucity of suitable cell types for cell replacement therapy in patients suffering from neurological disorders has hampered the development of this promising therapeutic approach. In recent years, neurons and glial cells have successfully been generated from stem cells such as embryonic stem cells, mesenchymal stem cells, and neural stem cells, and extensive efforts by investigators to develop stem cell‐based brain transplantation therapies have been carried out. We review here notable experimental and preclinical studies previously published involving stem cell‐based cell and gene therapies for Parkinson's disease, Huntington's disease, ALS, Alzheimer's disease, MS, stroke, spinal cord injury, brain tumor, and lysosomal storage diseases and discuss the future prospects for stem cell therapy of neurological disorders in the clinical setting. There are still many obstacles to be overcome before clinical application of cell therapy in neurological disease patients is adopted: 1) it is still uncertain what kind of stem cells would be an ideal source for cellular grafts, and 2) the mechanism by which transplantation of stem cells leads to an enhanced functional recovery and structural reorganization must to be better understood. Steady and solid progress in stem cell research in both basic and preclinical settings should support the hope for development of stem cell‐based cell therapies for neurological diseases. © 2009 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Corée du Sud</li><li>États-Unis</li></country><region><li>Californie</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Kim, Seung U" sort="Kim, Seung U" uniqKey="Kim S" first="Seung U." last="Kim">Seung U. Kim</name></noRegion><name sortKey="Kim, Seung U" sort="Kim, Seung U" uniqKey="Kim S" first="Seung U." last="Kim">Seung U. Kim</name></country><country name="Corée du Sud"><noRegion><name sortKey="Kim, Seung U" sort="Kim, Seung U" uniqKey="Kim S" first="Seung U." last="Kim">Seung U. Kim</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="De Vellis, Jean" sort="De Vellis, Jean" uniqKey="De Vellis J" first="Jean" last="De Vellis">Jean De Vellis</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000729 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000729 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:F588ED1FF799B4EAAFBE4AB8F6D25F4310AAA1B8
|texte= Stem cell‐based cell therapy in neurological diseases: A review
}}
| This area was generated with Dilib version V0.6.29. |  |